アメリカの自動微生物検査市場

◆英語タイトル:New Frontiers in the US Automated Microbiology Market: Business Challenges, Emerging Technologies, Competitive Landscape
◆発行会社/調査会社:Venture Planning Group
◆商品コード:VPAM8129
◆発行日:2014年5月
◆調査対象地域:アメリカ
◆ページ数:※レポート概要をご参照ください。
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Local LicenseUSD9,850 ⇒換算¥1,083,500見積依頼/購入/質問フォーム
Global LicenseUSD21,700 ⇒換算¥2,387,000見積依頼/購入/質問フォーム
DataPackUSD6,400 ⇒換算¥704,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Venture Planning Group社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[アメリカの自動微生物検査市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Complete report $9,850.  DataPack (test volumes, sales forecasts, supplier shares) $6,400.

New Frontiers in the U.S. Automated Microbiology Markets: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new analysis of the major business opportunities emerging in the automated microbiology market during the next five years.  The report examines key trends in the U.S. automated microbiology market; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology.  The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems.  The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies.  The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans.  Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies. 

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major suppliers of
microbiology products, by individual test.

- Five-year test volume and sales forecasts for over 100 microbiology
assays.

- Test volume estimates by method (molecular, serology/immunodiagnostics,
culture/microscopy).

U.S. Market Overview

- Review of the market dynamics, trends, structure, size, growth
and major suppliers.

- Estimated universe of laboratories performing microbiology testing.

- Specimen, test volume and sales forecasts.

Business Opportunities and Strategic Recommendations

- Emerging opportunities for new analyzers, reagents kits, IT
and other products with significant market appeal during the next five years.

- Design criteria for decentralized testing products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Specimen Types

- Urine
- Sterile Fluids: Blood, Serum, CSF
- Throat Swabs, Respiratory Secretions
- Genital Secretions
- Stool
- Abscess/Wound
- Sputum
- Saliva

Applications

- Microbial Identification
- Antibiotic Susceptibility
- Urine Screening
- Blood Cultures

Review of Major Automated Systems

- Review of major automated molecular diagnostic, multipurpose, specialized,
microbial identification, antibiotic susceptibility, blood culture, urine screening,
and immunodiagnostic analyzers.

- The report features analyzers manufactured by Abbott, Alifax, Anagen,
BD, Beckman Coulter/Danaher, Biochem, Biolog, bioMerieux, Bio-Rad,
Biotrol, Cepheid, Curetis, GenMark, Hologic/Gen-Probe, HTG, Iris, J&J,
Labsystems, Life Technologies, MiDI, Olympus, Qiagen, Roche, Siemens,
Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter,
Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium,
Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea,
Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme,
Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps,
Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia and others.

Technology Assessment

- Assessment of molecular diagnostic, monoclonal antibody,
immunoassay, and other technologies and their potential
applications for the microbiology market.

- Global listings of companies developing or marketing microbiology
products by individual test.

Competitive Strategies

- Strategic assessments of major suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.

- The companies analyzed in the report include: 

  – Abbott
  – Affymetrix
  – Agilent Technologies
  – Applied Gene Technologies
  – Arca/Nuvelo
  – Beckman Coulter/Danaher
  – Becton Dickinson
  – Biokit
  – bioMerieux         
  – Bio-Rad
  – Biotest
  – Caliper
  – Cepheid[u]
[/u]
  – Decode
  – Diadexus[u]
[/u]
  – Diamedix
  – DiaSorin[u]
[/u]
  – Eiken Chemical
  – Enzo Biochem[u]
[/u]
  – Exact Sciences[u]
[/u]
  – Fujirebio/Innogenetics
  – Hologic/Gen-Probe
  – Illumina
  – ID Biomedical/GSK[u]
[/u]
  – Kreatech
  – Li-Cor Biosciences
  – Lonza
  – Monogram Biosciences
  – Myriad Genetics
  – Nanogen/Elitech
  – Novartis Diagnostics/Grifols
  – Orchid CellMark
  – Ortho-Clinical Diagnostics
  – Proteome Sciences
  – Qiagen
  – Roche
  – Scienion
  – Sequenom[u]
[/u]
  – SeraCare
  – Siemens
  – Sierra Molecular
  – Shimadzu
  – Takara Bio
  – Tecan
  – Thermo Fisher/Life Technology
  – Wallac/PE
  – Wako

Contains 436 pages and 94 tables

*** レポート目次(コンテンツ)***

※目次は下記のURLでご確認ください。

http://www.vpgcorp.com/webfiles/MICROBIOLOGY/TOCLOTNewFrontiersintheUSAutomatedMicrobiologyMarketBusinessChallengesEmergingTechCompetitiveLandscape.pdf



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(VPAM8129 )"アメリカの自動微生物検査市場" (英文:New Frontiers in the US Automated Microbiology Market: Business Challenges, Emerging Technologies, Competitive Landscape)はVenture Planning Group社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。